LIXTE Biotechnology Holdings, Inc. announced the enrollment of the first patient in the Phase 1b portion of the Phase 1b/2 protocol (NCT05809830) to determine the appropriate dose of LB-100 given with a standard dose of doxorubicin. Once the dose is determined, a randomized Phase 2 study will be initiated seeking to gain evidence that the inclusion of doxorubicin increases time to a progression and/or overall survival of patients with advanced soft tissue sarcomas (ASTS).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.429 USD | +1.63% | -1.28% | +3.36% |
05-09 | Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-23 | Lixte Biotechnology Files Up to $50 Million Mixed Shelf | MT |
1st Jan change | Capi. | |
---|---|---|
+3.36% | 5.46M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- LIXT Stock
- News Lixte Biotechnology Holdings, Inc.
- LIXTE Biotechnology Holdings, Inc. Announces the Enrollment of the First Patient in the Phase 1b Portion of the Phase 1b/2 Protocol